Several brokerages have updated their recommendations and price targets on shares of Novavax (NASDAQ: NVAX) in the last few weeks:

  • 8/5/2017 – Novavax was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/27/2017 – Novavax was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/27/2017 – Novavax had its “neutral” rating reaffirmed by analysts at Chardan Capital. They now have a $1.50 price target on the stock.
  • 7/26/2017 – Novavax was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
  • 7/26/2017 – Novavax had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $1.50 price target on the stock.
  • 7/21/2017 – Novavax had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $2.00 price target on the stock. They wrote, “Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock.””
  • 7/19/2017 – Novavax was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 6/10/2017 – Novavax was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.25 price target on the stock. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “
  • 6/9/2017 – Novavax was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. “

Shares of Novavax, Inc. (NVAX) traded up 1.1561% during trading on Tuesday, reaching $0.9712. 4,268,502 shares of the company’s stock traded hands. The company has a 50 day moving average price of $1.17 and a 200-day moving average price of $1.16. The stock’s market cap is $274.46 million. Novavax, Inc. has a one year low of $0.73 and a one year high of $8.49.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The company had revenue of $5.68 million during the quarter, compared to analysts’ expectations of $6.17 million. During the same quarter in the prior year, the company posted ($0.29) EPS. The company’s revenue for the quarter was up 34.6% on a year-over-year basis. On average, equities research analysts expect that Novavax, Inc. will post ($0.61) EPS for the current fiscal year.

In related news, insider Stanley C. Erck acquired 50,000 shares of the stock in a transaction on Thursday, May 11th. The shares were acquired at an average price of $0.84 per share, for a total transaction of $42,000.00. Following the transaction, the insider now owns 128,279 shares in the company, valued at approximately $107,754.36. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders acquired 107,057 shares of company stock worth $92,631. Insiders own 4.00% of the company’s stock.

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Receive News & Ratings for Novavax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc and related companies with MarketBeat.com's FREE daily email newsletter.